If You Invested in Pharma-Bio Serv Inc (PBSV)
Looking for the live price? See the PBSV quote & overviewWhat $1,000 or $10,000 in PBSV Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jul 13, 2015 |
|---|---|---|---|---|
| $1,000 | $974 -3% | $459 -54% | $681 -32% | $565 -44% |
| $10,000 | $9,741 -3% | $4,593 -54% | $6,807 -32% | $5,650 -44% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for PBSV$1,000 Investment Over Time
PBSV vs S&P 500Year-by-Year Returns
PBSV annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2017 | $0.99 | $0.52 | -47.5% | -47.5% |
| 2018 | $0.52 | $1.00 | +92.3% | +1.0% |
| 2019 | $1.00 | $0.87 | -13.0% | -12.1% |
| 2020 | $0.87 | $1.45 | +66.7% | +46.5% |
| 2021 | $1.45 | $1.03 | -29.0% | +4.0% |
| 2022 | $1.03 | $0.79 | -23.3% | -20.2% |
| 2023 | $0.79 | $1.05 | +32.9% | +6.1% |
| 2024 | $1.05 | $0.55 | -47.6% | -44.5% |
| 2025 | $0.55 | $0.60 | +9.1% | -39.4% |
| 2026 | $0.54 | $0.56 | +4.6% | -42.9% |
About Pharma-Bio Serv Inc
Healthcare · OTC Link
Pharma-Bio Serv, Inc. (OTCQB:PBSV) is described in its public communications as a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm. The company provides services to clients in the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries. According to its news releases, Pharma-Bio Serv reports its financial results and business updates from Dorado, Puerto Rico.
Across multiple announcements, Pharma-Bio Serv characterizes its core activities as consulting and support services focused on compliance, project management and technology transfer. In some periods, the company also highlights regulatory affairs and quality as part of its service offering. These services are directed to organizations operating in regulated life sciences and related sectors, including pharmaceuticals, biotechnology, medical devices, cosmetics, food and allied products, and in certain releases, the chemical industry.
Business focus and client industries
Pharma-Bio Serv’s public disclosures emphasize that it works with companies that must meet regulatory, quality and compliance requirements. Its consulting work is described as supporting project management and technology transfer, and, in some communications, regulatory affairs and quality functions. The industries it serves, as stated in its releases, include:
- Pharmaceutical companies
- Biotechnology companies
- Chemical companies
- Medical device companies
- Cosmetic companies
- Food companies
- Allied products industries
The company presents itself as focusing on higher-value and high-margin services within these markets, and on projects that align with its expertise in compliance, project management and technology transfer support.
Strategic themes mentioned in company communications
In its earnings-related news releases, Pharma-Bio Serv discusses several recurring themes about how it manages its consulting business. The company has stated that it has:
- Streamlined its cost structure and prioritized core business segments.
- Exited less profitable areas to focus on higher-margin projects.
- Concentrated efforts on higher-value services and business development.
- Invested in technological tools to identify global business opportunities.
These themes appear in management commentary accompanying quarterly and annual results. The company links these actions to its goal of positioning itself for potential growth and adapting to conditions in the industries it serves.
Geographic scope as described by the company
In one of its quarterly announcements, Pharma-Bio Serv notes that it has projects underway in Europe, Asia and Latin America. In other releases, it refers to using technological tools to identify attractive global business opportunities and to participating in events at a global level. These statements indicate that, according to the company, its consulting projects and business development efforts extend beyond a single region.
Financial reporting and shareholder actions
Pharma-Bio Serv regularly issues press releases announcing results for quarters and full fiscal years, including revenues and net income or net loss for the reported periods. These releases describe how results compare with prior-year periods and often include commentary from the company’s Chief Executive Officer about business conditions and strategy. In some years, the company has also announced special dividends approved by its Board of Directors, specifying per-share amounts and record and payment dates.
An example is a release describing results for the year ended October 31, 2024, in which the company reported revenues and a net loss for that year and compared them with the prior year. In another release covering the year ended October 31, 2023, the company reported revenues and net income and discussed improvements in overall gross profit percentage. Separate announcements describe special dividends approved by the Board of Directors, with details on record dates and expected payment dates.
Regulatory disclosures
The company files reports with the U.S. Securities and Exchange Commission. A Form 8-K dated September 15, 2025 states that Pharma-Bio Serv issued a press release announcing its results of operations for the three and nine months ended July 31, 2025, and that the press release was furnished as an exhibit to that report. The filing notes that the information provided under that item is furnished rather than filed for purposes of certain sections of the Securities Exchange Act of 1934 and the Securities Act of 1933.
The Form 8-K lists Dorado, Puerto Rico in connection with the company’s address information. This aligns with the location references in its news releases, which are datelined Dorado, Puerto Rico or Dorado, PR.
Position within sector and industry classification
For classification purposes, Pharma-Bio Serv is associated with the Professional, Scientific, and Technical Services sector and the Testing Laboratories industry. Its own descriptions, however, focus on consulting services in regulatory affairs, quality, compliance, project management and technology transfer support for life sciences and related industries. This combination places the company within a segment of the professional services market that serves regulated sectors such as pharmaceuticals, biotechnology, medical devices, cosmetics, food and allied products, and, in some communications, chemicals.
Approach to markets and services (as described by the company)
In its public statements, Pharma-Bio Serv refers to several approaches it is taking in its markets:
- Concentrating on high-margin yielding projects.
- Redirecting resources toward business development and adoption of advanced technologies.
- Strengthening business development infrastructure and increasing targeted actions in high-revenue markets.
- Pursuing opportunities in new and targeted markets, including underserved markets.
The company links these approaches to goals such as achieving sustainable growth, minimizing revenue fluctuations and pursuing opportunities in global markets. It also refers to delivering premium quality and professional consulting services, as described in its news releases.
Stock information
Pharma-Bio Serv’s news releases identify the company’s trading symbol as PBSV and indicate that its shares are quoted on the OTCQB market. Investors and analysts looking at PBSV can review the company’s periodic news releases and SEC filings to understand its reported financial performance, strategic focus and the industries it serves.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Pharma-Bio Serv Inc investment returns
How much would $1,000 invested in Pharma-Bio Serv Inc be worth today?
If you invested $1,000 in Pharma-Bio Serv Inc (PBSV) 10 years ago on 2016-07-11, your investment would be worth $681 today, representing a -31.9% total return, growing at a compounded rate of -3.8% per year (CAGR).
Has Pharma-Bio Serv Inc outperformed the S&P 500?
Over the past 10 years, PBSV returned -31.9% compared to +252.3% for the S&P 500, underperforming the benchmark by 284.2 percentage points.
What is Pharma-Bio Serv Inc's average annual return?
The compound annual growth rate (CAGR) of PBSV over the past 10 years is -3.8%, growing at a compounded rate each year. Individual years vary significantly — PBSV's best recent year was 2018 (+92.3%) and worst was 2024 (-47.6%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
